Cilofungin (LY121019) is a semisynthetic antifungal drug that is active in vitro and in vivo against Candida albicans (4, 9) . Its antifungal activity is due to inhibition of the synthesis of beta-glucan, a component of fungal cell wall. Studies indicate that cilofungin may be fungicidal in vivo (4) .
The purposes of these studies were (i) to evaluate the efficacy of cilofungin for treatment of experimental candidal endocarditis in rabbits, (ii) to determine whether cilofungin is fungicidal in an experimental model in which host defenses play little or no role, and (iii) to compare the efficacy of cilofungin with that of amphotericin B.
A Experimental aortic valve endocarditis was established as described previously (8) all survived the 4 days of therapy (P = 0.006 versus no treatment), and the vegetation titers were significantly lower (P = 0.001) than those in untreated rabbits.
Endocarditis is a severe test of drug efficacy because host defenses are impaired. Phagocytic cells are absent in mature vegetations of bacterial (2) and fungal (1) endocarditis. For both bacterial and fungal endocarditis (1, 10), titers in vegetations are several times higher in vivo than is commonly tested in vitro. Antibiotic penetration into the vegetation can be impaired (5, 7) . Metabolic activity of the organisms in the vegetation is decreased compared with that in vitro (2) . Drugs may be effective only if organisms are metabolically active and dividing. Similar to the beta-lactam antibiotics in terms of bactericidal activity, cilofungin and related agents are fungicidal only against growing fungal organisms (6, 11).
In our studies cilofungin did not reduce the number of organisms in vegetations compared with those in controls. This suggests that cilofungin was not fungicidal in this model.
Other investigators have seen a good correlation between activity of cilofungin in vitro and efficacy in vivo, and cilofungin has been compared favorably to amphotericin B (4, 9) . In these other studies, the animal models used either had intact host defenses or modestly impaired defenses with a Mean value for eight control rabbits, because vegetation titers for the five rabbits sacrificed at 24 h and the three allowed to survive were similar. neutrophil counts of 1,000 or more cells per mm3 (3) . The sites of infection were skin, mucosa, or soft tissue.
Cilofungin may have been effective for these infections and not endocarditis, because endocarditis is a more severe infection with more impaired host defenses. If drug penetration also was impaired (clearance of cilofungin was relatively rapid in vivo) and fungal cells were relatively inactive metabolically, this could also have contributed to the lack of efficacy of cilofungin in endocarditis.
These studies suggest that cilofungin may not be reliably fungicidal in vivo. Cilofungin may be intrinsically fungistatic. Alternatively, although relatively large doses were used, cilofungin may be fungicidal only at larger doses, producing even higher concentrations in serum than those that were achieved in this model. For serious candidal infections in the severely immunocompromised host, especially the neutropenic patient, cilofungin may not be as effective as amphotericin B.
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